Microrna Based Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally. Dysregulation of specific miRNAs has been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). miRNA-based therapeutics include miRNA mimics (to restore lost function) and miRNA inhibitors (antagomirs/antisense) to block pathological overexpression. These approaches offer precision targeting of disease pathways.
miRNA-based therapies work through several mechanisms:
| Mechanism | Description |
|---|---|
| miRNA Mimics | Double-stranded RNAs that restore deficient miRNA function |
| miRNA Inhibitors | Single-stranded antisense oligonucleotides (antagomirs) |
| miRNA Sponges | Transgenic expression to sequester specific miRNAs |
| Seed Targeting | Blockade of miRNA seed region to inhibit family members |
| miRNA | Target Disease | Mechanism | Development Stage |
|---|---|---|---|
| miR-29 | AD | Downregulate BACE1; reduce Aβ production | Preclinical |
| miR-124 | AD/PD | Promote neurogenesis; reduce neuroinflammation | Preclinical |
| miR-132 | AD | Enhance neuronal survival; reduce tau pathology | Preclinical |
| miR-7 | PD | Reduce α-synuclein expression | Preclinical |
| miR-153 | AD/PD | Suppress amyloid and α-synuclein | Preclinical |
| miRNA | Target Disease | Mechanism | Development Stage |
|---|---|---|---|
| miR-29b | AD | Inhibit BACE1 expression | Preclinical |
| miR-155 | AD/PD/MS | Reduce neuroinflammation | Preclinical |
| miR-21 | PD/ALS | Modulate apoptosis | Preclinical |
| miR-9 | ALS | Target SOD1 | Preclinical |
| miR-17-92 cluster | HD | Modulate mutant huntingtin | Preclinical |
Key miRNA targets:
Approach: miRNA mimics to restore protective miRNAs, inhibitors to block pathological overexpression
Key miRNA targets:
Approach: miR-7 and miR-153 mimics show neuroprotection in models
Key miRNA targets:
Approach: Combination approaches targeting multiple pathways
Key miRNA targets:
Approach: Antagomirs to reduce pathological miRNA levels
| Trial | Therapy | Target | Phase | Status | Indication |
|---|---|---|---|---|---|
| NCT05525485 | miR-29 mimic | AD | Preclinical | Preclinical | Alzheimer's disease |
| - | miR-124 mimic | PD/AD | Preclinical | Preclinical | Parkinson's disease |
| - | miR-155 inhibitor | ALS | Preclinical | Preclinical | ALS |
Note: Most miRNA therapies remain in preclinical development for neurodegeneration
miRNAs in cerebrospinal fluid (CSF) and blood serve as disease biomarkers:
| miRNA | Disease | Application |
|---|---|---|
| miR-29 family | AD | Diagnostic; disease progression |
| miR-124 | AD/PD | Neuronal loss marker |
| miR-153 | AD | Aβ burden |
| miR-7 | PD | Diagnostic |
| miR-9 | ALS | Disease progression |
Current research focuses on:
The study of Microrna Based Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.